Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
about
Principal component analysis-based unsupervised feature extraction applied to in silico drug discovery for posttraumatic stress disorder-mediated heart diseasetRNA binding to antitumor drug doxorubicin and its analogueMyocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosisPaving the Route to Plasma miR-208a-3p as an Acute Cardiac Injury Biomarker: Preclinical Rat Data Supports Its Use in Drug Safety Assessment.Distinctive profile of IsomiR expression and novel microRNAs in rat heart left ventricle.Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer PatientsAltered serum microRNAs as novel diagnostic biomarkers for atypical coronary artery disease.Heart structure-specific transcriptomic atlas reveals conserved microRNA-mRNA interactions.Identification of General and Heart-Specific miRNAs in Sheep (Ovis aries)Comment on "MicroRNA-208a Silencing Attenuates Doxorubicin Induced Myocyte Apoptosis and Cardiac Dysfunction"Doxorubicin induced heart failure: Phenotype and molecular mechanisms.Regulation of cardiac microRNAs by cardiac microRNAs.MicroRNA-34a regulates doxorubicin-induced cardiotoxicity in rat.Circulating miR-1 as a potential biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Noncoding RNA response to xenobiotic exposure: an indicator of toxicity and carcinogenicity.The role for microRNAs in drug toxicity and in safety assessment.Alternative Biomarkers for Combined Biology.MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.MicroRNA Regulatory Network Revealing the Mechanism of Inflammation in Atrial Fibrillation.Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.Activation of miR-34a-5p/Sirt1/p66shc pathway contributes to doxorubicin-induced cardiotoxicity.Sarco"MiR" friend or foe: a perspective on the mechanisms of doxorubicin-induced cardiomyopathy.Magnetic ligation method for quantitative detection of microRNAs.Technological Advances in Cardiovascular Safety Assessment Decrease Preclinical Animal Use and Improve Clinical Relevance.The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients.Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy.Doxorubicin and Liposomal Doxorubicin Differentially Affect Expression of miR-208a and let-7g in Rat Ventricles and Atria.Circulating mir-208a fails as a biomarker of doxorubicin-induced cardiotoxicity in breast cancer patients.Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients.The Cardiotoxic Mechanism of Doxorubicin (DOX) and Pegylated Liposomal DOX in Mice Bearing C-26 Colon Carcinoma: a Study Focused on microRNA Role for Toxicity Assessment of New Formulations.Protecting the heart in cancer therapy
P2860
Q28395122-AF256F99-513C-48AF-B8FD-E29FFCC26E95Q28534958-295423B0-C86A-40EC-91BF-91DF7C068704Q28573405-0BD66565-135F-47AF-8669-57A59AF94FF3Q31004210-DE3CB9BA-286D-4F7C-A55E-46BFEBB164B5Q31120462-36A96A03-123B-4627-8DD3-05D5738FE18EQ33816471-5773A1A0-E21D-44AF-AFF1-DB5EF3BA8643Q34150002-273218B8-4D99-41FA-ADE3-5C8B8F993E90Q34542113-4CD5014B-6941-47C2-98D5-A093983016F8Q35849561-2634FDD6-D1E7-4AA1-A440-EF36CB05E6FCQ36409311-54E22B58-7895-480B-9E85-E58F5B4410FCQ36912561-03808EBA-BA8F-40D2-ACE9-DBF91ACDB2F8Q37162692-3CD90C2B-F86C-4BA6-81CF-2012F91DEADAQ37641769-B253E74C-76CE-46C0-B9B1-FC6E180B12AAQ37701713-07E8B5FE-675D-453E-B4E9-83F0290F3C31Q38166071-075EC224-878C-4EA1-9BE0-53F46A22BDF0Q38244618-B2A5FC10-F252-40E9-ABED-1D5BEC96E74CQ38367620-B5A3BBDF-A737-42B5-A9AC-E4EC325B269FQ38747992-6A5FDCDA-0CDB-4791-A01A-2D4679378C4CQ40026732-4F7FA7DE-257D-4FD0-A497-1F781A1CD2B6Q40322528-B4007F76-8528-4647-A4D1-C4250C22D103Q41165846-CC8F3ADF-5F88-49E7-AFC0-EEC6DA8EA3CBQ41717594-7116F1EE-1622-47B9-9B98-1838CE262ADDQ41983421-20DBED99-86AC-48D9-A2DC-CB7AB400B266Q42743719-3BE982D6-11DE-46C8-9BFA-5B5BADD2204FQ45967235-78EEEF24-CFD9-4709-A84A-73EB650507BDQ46269647-B9880F28-6D40-4C62-BAA8-8A4D179B55E1Q47929107-FC3D032B-E192-4313-8561-18800D530EF0Q47943382-FB456DD8-6D81-44FC-94F0-80A60DDEF08DQ48141841-062E6954-253F-43BA-B859-AA66ED1E077DQ48178650-CF4E6082-6575-4827-B60A-1B68BECDAA97Q49163835-56AB3D9F-531F-4D52-84A5-CB95F26D714CQ50611647-B5831CBA-8269-4E1F-9768-6D7C0369B8E8Q57821006-68C2D0A5-1904-4717-90B2-50D3C3D99DD0
P2860
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@ast
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@en
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@nl
type
label
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@ast
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@en
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@nl
prefLabel
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@ast
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@en
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@nl
P2093
P2860
P1433
P1476
Perturbation of microRNAs in rat heart during chronic doxorubicin treatment
@en
P2093
Brian R Berridge
Caterina Vacchi-Suzzi
Frank Staedtler
François Pognan
Hisham K Hamadeh
Jonathan Lyon
Jonathan Moggs
Kevin Gerrish
Martin Letzkus
Martin P Vidgeon-Hart
P2860
P304
P356
10.1371/JOURNAL.PONE.0040395
P407
P577
2012-01-01T00:00:00Z